1. Introduction

Myotonic dystrophy type 1 (DM1) is the most common autosomal dominant muscular dystrophy of the adulthood age, affecting the skeletal and smooth muscles, together with a multisystem involvement. The prevalence differs widely between countries, with a mean of 13/100,000 inhabitants. The disease is caused by expansion of a cytosine, guanine, thymine (CTG) trinucleotide repeat in the non-coding region of dystrophia myotonica protein kinase gene, located on chromosome 19. According to the Tsillids scale, depending on the CTG expansion size, we can identify 4 DM1 classes: E0 (38–79), E1 (80–499), E2 (500–999), E3 (1000–1499), and E4 (>1500) (3). Indeed, when CTG repeat sequences are between 38 and 49, patients may do not clinically manifest the disease (but their offspring may have a substantial risk to show clinical DM1 symptoms), whereas individuals with >50 repeat sequences would manifest the DM1 phenotype. These repeatedly amplified sequences are located in the untranslated regions of disease-causing genes and do not change the protein encoding for their location genes. The synergistic effects of various mechanisms, that is, ribonucleic acid (RNA) toxicity associated to a spliceopathy and to the entail regulation of gene expression and translation, are likely to induce the multisystem damage associated with DM1. To date, apart from retrospective analyses concerning the myotonic dystrophies-associated risk of cancer, there have been shown an association between DM1 and benign cutaneous lesions, that is, dysplastic nevi, alopecia, pilomatricomas, xerosis, and seborrheic dermatitis. Among such benign abnormalities, there are hemangiomas, considered the most common benign tumor of vascular origin, due to the proliferation of endothelial cells, with a typical slow progression. Oral lesions generally appear on the lips, buccal mucosa, and tongue. However, the majority of hemangiomas involve head and neck and they are rare in the oral cavity, possibly occurring even in tongue. They present as a red macula, papule or nodule, depending on the depthness in the tissue and on the congestion degree.

To date, no data are reported on the presence of multiple hemangiomas of the tongue and the oral cavity in DM1. Herein, we report on a 63-year-old woman affected by DM1, presenting...
with tongue hemangiomas, with no further benign or malignant associated tumors.

2. Case report

A 63-year-old woman was admitted to our Research Institute because of difficulty to open the fist after a strong muscle contraction, muscle stiffness, and weakness at lower limbs, with walking difficulties, tongue and jaw myotonia, and slurred speech. Family history was positive for early cataracts and baldness. At the age of 30, she underwent a surgery for bilateral cataract. She presented headache on awakening and daytime sleepiness. At neurological examination, she had difficulty to open the fist after a strong muscle contraction (myotonic phenomenon); percussion myotonia was present in the bilateral thenar muscles. She presented a light waddling gait with a bilateral “steppage,” and she was not able to walk on heels. She was able to climb the stairs and rise from a chair only with bilateral support. Gowers maneuver was positive. Flexor neck muscles, sternocleidomastoids, digital extensors and flexors, and bilateral foot dorsi flexors muscles were weak. Deep tendon reflexes were absent. She showed a myopathic pattern with myotonic discharges at the neurophysiological study. Intraoral examination revealed several swelling lesions occurring on buccal and palatal mucosa, and in the anterior two-thirds and margins of the tongue (Fig. 1). These lesions showed a bluish discoloration with intact overlying mucosa. They were soft in consistency and non-tender on palpation. Color Doppler ultrasound revealed hypoechoic lesions with intermittent color picking suggestive of vascular lesion. Surgical excision was performed under general anesthesia; histopathological examination confirmed the definite diagnosis of cavernous hemangioma, managed with a conservative approach. Specifically, the lesion was resected, preserving, and maintaining the tongue function. Blood test, including glucose, liver and renal function, cardiac enzymes, and thyroid function were normal, as well as echocardiography. The electrocardiogram revealed arrhythmias with atrial fibrillation and a right bundle-branch block. Spirometry showed a restrictive respiratory failure. Considering such clinical phenotype, together with the family history of early-onset cataract and baldness (which are some of the DM1 clinical features), a DM1 diagnosis was supposed and confirmed by the molecular genetic analysis, showing a 590 CTG repeats in the untranslated region of the dystrophia myotonica protein kinase gene (DMPK). The patient has provided informed consent for publication of the case.

3. Discussion

In the last years, several studies have been performed to better define a possible cutaneous “phenotype” of DM1, within the well-known multisystem involvement.[5,8–10,11] As far as we know, the molecular pathogenesis of DM1 is considered to be mediated by toxic RNA with disruption of splicing of pre-mRNA transcripts including CUG binding protein (CUG-BP) and Musclebind-like protein (MBNL).[1,11] Such RNA toxicity mediated process is commonly known as “spliceopathy.”[2,12] In DM1, MBNL is sequestered in the nucleus and unable to be utilized by the cell (RNA “loss of function”). CUG-BP, conversely, is elevated in DM1 (RNA “gain of function”) via increased activation and phosphorylation through several other protein mediators such as protein kinase C.[1,11] CUG-BP elevation has been noted to inhibit myoblast differentiation, reducing DNA repair, and result in loss of CLCN1 chloride channels through disruption of alternative splicing.[1,11] Recent studies have suggested that DM1 is associated to an increased risk of benign and malignant tumors. Moreover, some authors have studied the relationship between gene mutation and skin tumors, which are the most frequent cancers in DM1 patients, noting that CTG repeat expansion is higher in tumor than in non-tumor tissues.[9,13] The increased predisposition to cancer in such patients may be related to the increased repeat sequences leading to a DMPK instability[1,11] thus increasing the predisposition to develop cancers.[8,12] Moreover, Mueller et al.[14] have recently shown the possible role of the upregulation of the β-catenin in tumor progression in DM1, via the Wnt signaling pathway, possibly through the actions of CUG-BP or MBNL. Moreover,
CUG-BP has been shown to block calcireticulin-mediated repression of p21 translation,\textsuperscript{[13]} whose expression has been found increased in thymomas, one of the more commonly reported neoplasms in DM1 patients.\textsuperscript{[16]} Furthermore, p21 plays a major role in oncogenesis, and has also been implicated in apoptosis, terminal differentiation, and replicative senescence via interactions with such well-known tumor suppressor genes as p53 and BRCA1, as well genes in the Wnt/β-catenin signaling pathway.\textsuperscript{[17,18]}

Although the functional role of DMPK has not been fully described yet, there is some evidence about its role in Ca\textsuperscript{2+} homeostasis and signal transduction.\textsuperscript{[15]} In fact, in epidermal cells, calcium modulates both cell behavior and differentiation, so that, at lower calcium concentrations (0.02–0.01 mM), there is a higher cell proliferation rate and a lower terminal differentiation and vice versa.\textsuperscript{[19]}

In order to assess this risk, in 2012 Zampetti et al\textsuperscript{[9]} screened 90 DM1 patients for dysplastic nevi, cutaneous melanoma, and other skin neoplasms, demonstrating a higher prevalence of skin tumors than in the control group, and suggesting a striking predisposition for these patients to develop dysplastic nevi, cutaneous melanoma, and pilomatrixoma. These data are in agreement with previous findings on a possible association between DM1 and melanoma/non-melanoma skin cancers (NMSC) and less common cutaneous neoplasms\textsuperscript{[11,13,20,21]} as also suggested by a large retrospective analysis of 499 patients with DM1 focused on the prevalence of all types of tumors.\textsuperscript{[1]} To overcome the main limitation of the study by Zampetti et al\textsuperscript{[9]} that is, the lack of a standardized technique for the assessment of prior sun exposure, a more recent study by Bianchi et al\textsuperscript{[10]} specifically assessed for lifestyle factors on a cohort of 255 DM1 patients, demonstrating that there was no association between tumor developments and evaluated personal behaviors. In this paper, the authors concluded that the lack of an association between common cancer risk factors and tumor development in DM1 seemed to support a pathogenic link between tumors and DM1 itself, emphasizing the need for a systematic surveillance.\textsuperscript{[3]}

However, recently, Gadalla et al\textsuperscript{[22]} suggested that the risk factors for malignant skin tumors in DM1 strongly resemble the general population, thus recommending that DM1 patients had to adhere to sun exposure protective behavior.

Regarding hemangiomas, these are benign lesions, due to the proliferation of endothelial cells, usually located in the head and neck region is more commonly affected especially the face, oral mucosa, lips, tongue, and trunk.\textsuperscript{[23]} The term cavernous hemangioma has traditionally been applied when lesions involving a molecular dysregulation of cell proliferation that DM1 disease implies. Moreover, since hemangiomas may cause functional problems with speaking, mastication, and deglutition, they may apparently worsen the clinical picture of DM1, which cause itself those disturbances. Further studies are needed to deeply investigate and to better evaluate such coexistence in a larger sample of DM1 patients.

Moreover, in the present case, we used Color Doppler ultrasound to identify the feeding vessel, and to make easier the differential diagnosis between vascular and non-vascular lesions.

Hemangiomas of the tongue are rare lesions which can cause distressing problem to the patients, producing cosmetic deformity, recurrent hemorrhage, and functional problems with speaking, mastication, and deglutition. The treatment depends on lesion location, size and evolution stage, and the patient’s age.

Management of hemangioma depends on a variety of factors, and most true hemangioma requires no intervention and the wait and watch policy, as we did in our case.

However, in cases requiring treatment, intralesional and systemic corticosteroid treatment, embolization, excision, electrolysis and thermocoagulation, sclerotherapy/laser therapy, immunomodulatory therapy with interferon alfa-2a, and laser photocoagulation are the reported applied techniques.\textsuperscript{[27]}

Conservative or aggressive treatment may be tried for the hemangiomas of the tongue. However, both treatment methods have disadvantages. In the conservative treatment, recurrences may be frequent. On the other hand, aggressive treatment could also cause function loss.\textsuperscript{[24,25]} However, the results of cryotherapy have been reported to have high success rates. Kutluhan used plasma knife surgery for excision of hemangioma of tongue.\textsuperscript{[28]}

Considering the frequency of tongue hemangiomas in the general population, it is difficult to establish if the association between DM1 and tongue hemangiomas is casual or part of the multimystem involvement with a complex pathogenic mechanism involving a molecular deregulation of cell proliferation that DM1 disease implies. Moreover, since hemangiomas may cause functional problems with speaking, mastication, and deglutition, they may apparently worsen the clinical picture of DM1, which cause itself those disturbances. Further studies are needed to deeply investigate and to better evaluate such coexistence in a larger sample of DM1 patients.

Author contributions

Conceptualization: Simona Portaro, Giuseppe Di Toro, Rocco Salvatore Calabrò.

Data curation: Simona Portaro, Antonino Naro, Claudio Guarneri, Giuseppe Di Toro, Alfredo Manuli.

Investigation: Antonino Naro, Claudio Guarneri, Alfredo Manuli, Rocco Salvatore Calabrò.

Methodology: Simona Portaro, Antonino Naro, Claudio Guarneri, Giuseppe Di Toro, Rocco Salvatore Calabrò.

Supervision: Rocco Salvatore Calabrò.

Validation: Simona Portaro, Claudio Guarneri, Giuseppe Di Toro, Alfredo Manuli.

Visualization: Antonino Naro, Alfredo Manuli.

Writing – original draft: Simona Portaro.

Writing – review & editing: Rocco Salvatore Calabrò.

References

[1] Thornton CA. Myotonic dystrophy. Neurol Clin 2014;32:705–19.
[2] Wang Y, Pfeiffer RM, Alsaagat R, et al. Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink. Int J Cancer 2018;142:1174–81.
[3] Marcoval J, Olivé M, Bonfill-Oritz M, et al. Cutaneous neoplasms in myotonic dystrophy type 1. Dermatolog int 2016;232:700–3.
[4] Campione E, Bott A, Di Prere M, et al. Cutaneous features of myotonic dystrophy types 1 and 2: implication of premature aging and vitamin D homeostasis. Neuromuscul Disord 2017;27:163–9.
[5] Sherrod QJ, Chiu MW, Gutierrez M. Multiple pilomatricomas: cutaneous marker for myotonic dystrophy. Dermatol Online J 2008; 14:22.

[6] Shamloo N, Lotfi A, Motazazdan HR, et al. Squamous cell carcinoma as the most common lesion of the tongue in Iranians: a 22-year retrospective study. Asian Pac J Cancer Prev 2016;17:1415–9.

[7] Singh P, Parikh AS, Siddique SN, et al. Capillary haemangioma on the palate: a diagnostic conundrum. BMJ Case Rep 2016;16:pii:bcr2015210948.

[8] Zemtsov A. Association between basal, squamous cell carcinomas, dysplastic nevi and myotonic muscular dystrophy indicates an important role of RNA-binding proteins in development of human skin cancer. Arch Dermatol Res 2010;302:169–70.

[9] Zampetti A, Silvestri G, Manco S, et al. Dysplastic nevi, cutaneous melanoma, and other skin neoplasms in patients with myotonic dystrophy type 1: a cross-sectional study. J Am Acad Dermatol 2015;72:85–91.

[10] Bianchi ML, Leoncini E, Masciullo M, et al. Erratum to: Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors. J Neurol 2016;263:499.

[11] Timchenko LT, Timchenko NA, Caskey CT, et al. Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: implications for myotonic dystrophy. Hum Mol Genet 1996;5:115–21.

[12] Ueda H, Ohno S, Kobayashi T. Myotonic dystrophy and myotonic dystrophy protein kinase. Prog Histochem Cytochem 2000;35:187–251.

[13] Itin PH, Laeng RH. Multiple pigmented basal celloma of the scalp in a patient with Curschmann-Steinert myotonia dystrophica. Confirmation of a rare symptom constellation. Hautarzt 2001;52:244–6.

[14] Mueller CM, Hilbert JE, Martens W., et al. Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 2009;20:2009–20.

[15] Isakov P, Wang GL, Timchenko L, et al. Competition of CUGBP1 and calreticulin for the regulation of p21 translation determines cell fate. EMBO J 2004;23:406–17.

[16] Makai K, Sato Y, Hirohashi S, et al. Expression of ras p21 protein by thymoma. Virchows Arch B Cell Pathol Incl Mol Pathol 1996;59:11–6.

[17] Saegusa M, Hashimura M, Kuwata T, et al. Beta-catenin simultaneously induces activation of the p53-p21WAFl pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am J Pathol 2004;164:1739–49.

[18] Kames J, Toyofuku T, Hori M. Negative regulation of p21 by beta-catenin/TCF signaling: a novel mechanism by which cell adhesion molecules regulate cell proliferation. Biochem Biophys Res Commun 2003;312:380–7.

[19] Jensen PK, Norgård JO, Knudsen C, et al. Effects of extra- and intracellular calcium concentration on DNA replication, lateral growth, and differentiation of human epidermal cells in culture. Virchows Arch B Cell Pathol Incl Mol Pathol 1990;59:17–25.

[20] Bariuls J, Botella R, Palau F, et al. Tissue and tumor mosaicism of the myotonic protein kinase gene trinucleotide repeat in a patient with multiple basal cell carcinomas associated with myotonic dystrophy. J Am Acad Dermatol 2004;50(suppl):S1–3.

[21] Berberian BJ, Colonna TM, Battaglia M, et al. Multiple pilomatricomas in association with myotonic dystrophy and a family history of melanoma. J Am Acad Dermatol 1997;37:268–9.

[22] Gadalla SM, Hilbert JE, Martens WB, et al. Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy. Eur J Neurol 2017;24:713–8.

[23] Bone- Coloma C, Minguez-Martinez I, Palma-Carrió C, et al. Clinical characteristics, treatment and outcome of 28 oral hemangiomas in pediatric patients. Med Oral Patol Oral Cir Bucal 2011;16:e19–22.

[24] Avila ED, Molon RS, Comte Neto N, et al. Lip cavernous hemangioma in a young child. Braz Dent J 2010;21:170–4.

[25] Slaba S, Braidy C, Sader RB, et al. Giant venous malformation of the tongue: the value of surgi...